Literature DB >> 16822590

Morphological alterations and induction of oxidative stress in glial cells caused by the branched-chain alpha-keto acids accumulating in maple syrup urine disease.

Cláudia Funchal1, Alexandra Latini, Maria Caroline Jacques-Silva, André Quincozes Dos Santos, Luciane Buzin, Carmem Gottfried, Moacir Wajner, Regina Pessoa-Pureur.   

Abstract

Maple syrup urine disease (MSUD) is an inherited neurometabolic disorder biochemically characterized by the accumulation of the branched-chain alpha-keto acids (BCKA) alpha-ketoisocaproic (KIC), alpha-keto-beta-methylvaleric (KMV) and alpha-ketoisovaleric (KIV) and their respective branched-chain alpha-amino acids in body fluids and tissues. Affected MSUD patients have predominantly neurological features, including cerebral edema and atrophy whose pathophysiology is not well established. In the present study we investigated the effects of KIC, KMV and KIV on cell morphology, cytoskeleton reorganization, actin immunocontent and on various parameters of oxidative stress, namely total antioxidant reactivity (TAR), glutathione (GSH) and nitric oxide concentrations, and on the activities of catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GPx) in C6 glioma cells. We initially observed that C6 cultivated cells exposed for 3 h to the BCKA (1 and 10 mM) changed their usual rounded morphology to a fusiform or process-bearing cell appearance, while 24 h exposure to these organic acids elicited massive cell death. Rhodamine-labelled phalloidin analysis revealed that these organic acids induced reorganization of the actin cytoskeleton with no modifications on total actin content. It was also observed that 3h cell exposure to low doses of all BCKA (1 mM) resulted in a marked reduction of the non-enzymatic antioxidant defenses, as determined by TAR and GSH measurements. In addition, KIC provoked a reduced activity of SOD and GPx, whereas KMV caused a diminution of SOD activity. In contrast, CAT activity was not modified by the metabolites. Furthermore, nitric oxide production was significantly increased by all BCKA. Finally, we observed that the morphological features caused by BCKA on C6 cells were prevented by the use of the antioxidants GSH (1.0 mM), alpha-tocopherol (trolox; 10 microM) and Nomega-nitro-L-arginine methyl ester (L-NAME; 500 microM). These results strongly indicate that oxidative stress might be involved in the cell morphological alterations and death, as well as in the cytoskeletal reorganization elicited by the BCKA. It is presumed that these findings are possibly implicated in the neuropathological features observed in patients affected by MSUD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16822590     DOI: 10.1016/j.neuint.2006.05.007

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  24 in total

1.  Effect of the atypical neuroleptic risperidone on morphology and S100B secretion in C6 astroglial lineage cells.

Authors:  André Quincozes-Santos; Renata Torres Abib; Marina Concli Leite; Daiane Bobermin; Victorio Bambini-Junior; Carlos-Alberto Gonçalves; Rudimar Riesgo; Carmem Gottfried
Journal:  Mol Cell Biochem       Date:  2008-04-18       Impact factor: 3.396

Review 2.  Metabolism in cardiomyopathy: every substrate matters.

Authors:  Julia Ritterhoff; Rong Tian
Journal:  Cardiovasc Res       Date:  2017-03-15       Impact factor: 10.787

Review 3.  Branched-chain amino acids in metabolic signalling and insulin resistance.

Authors:  Christopher J Lynch; Sean H Adams
Journal:  Nat Rev Endocrinol       Date:  2014-10-07       Impact factor: 43.330

4.  Acute and long-term effects of intracerebroventricular administration of α-ketoisocaproic acid on oxidative stress parameters and cognitive and noncognitive behaviors.

Authors:  Luciane Taschetto; Giselli Scaini; Hugo G Zapelini; Ândrea C Ramos; Giulia Strapazzon; Vanessa M Andrade; Gislaine Z Réus; Monique Michels; Felipe Dal-Pizzol; João Quevedo; Patrícia F Schuck; Gustavo C Ferreira; Emilio L Streck
Journal:  Metab Brain Dis       Date:  2017-05-27       Impact factor: 3.584

Review 5.  Cytoskeleton as a potential target in the neuropathology of maple syrup urine disease: insight from animal studies.

Authors:  R Pessoa-Pureur; M Wajner
Journal:  J Inherit Metab Dis       Date:  2007-06-14       Impact factor: 4.982

6.  Profiling of oxidative stress in patients with inborn errors of metabolism.

Authors:  Peter J Mc Guire; Aditya Parikh; George A Diaz
Journal:  Mol Genet Metab       Date:  2009-06-14       Impact factor: 4.797

7.  Divergent Induction of Branched-Chain Aminotransferases and Phosphorylation of Branched Chain Keto-Acid Dehydrogenase Is a Potential Mechanism Coupling Branched-Chain Keto-Acid-Mediated-Astrocyte Activation to Branched-Chain Amino Acid Depletion-Mediated Cognitive Deficit after Traumatic Brain Injury.

Authors:  Guoqiang Xing; Ming Ren; Ajay Verma
Journal:  J Neurotrauma       Date:  2018-07-11       Impact factor: 5.269

8.  L-carnitine Prevents Oxidative Stress in the Brains of Rats Subjected to a Chemically Induced Chronic Model of MSUD.

Authors:  Caroline Paula Mescka; Andrea Pereira Rosa; Gabriel Schirmbeck; Thales Hein da Rosa; Felipe Catarino; Laila Oliveira de Souza; Gilian Guerreiro; Angela Sitta; Carmen Regla Vargas; Carlos Severo Dutra-Filho
Journal:  Mol Neurobiol       Date:  2015-11-02       Impact factor: 5.590

9.  Gliopreventive effects of guanosine against glucose deprivation in vitro.

Authors:  André Quincozes-Santos; Larissa Daniele Bobermin; Débora Guerini de Souza; Bruna Bellaver; Carlos-Alberto Gonçalves; Diogo Onofre Souza
Journal:  Purinergic Signal       Date:  2013-07-12       Impact factor: 3.765

10.  Protein phosphatase 2Cm is a critical regulator of branched-chain amino acid catabolism in mice and cultured cells.

Authors:  Gang Lu; Haipeng Sun; Pengxiang She; Ji-Youn Youn; Sarah Warburton; Peipei Ping; Thomas M Vondriska; Hua Cai; Christopher J Lynch; Yibin Wang
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.